Phaseline

Targets › VKORC1

VKORC1 (Vitamin K epoxide reductase complex subunit 1): drug programs, companies and trials

7 programs from 7 companies in 7 trials: 5 Phase 4, 2 Phase 3; Cardiovascular, Other, Genitourinary; next expected readout Dec 2026.

Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development. (UniProt, Q9BQB6)

Open in Phaseline: the race on VKORC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital Sirio-LibanesWarfarin
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
VKORC1Phase 4Atrium; FibrillationDec 2026
Nicholas CarlsonWarfarin
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
VKORC1Phase 4Atrial Fibrillation and FlutterJan 2027
Columbia UniversityWarfarin
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
VKORC1Phase 4BleedingApr 2027
University of MichiganVitamin K
Vitamin K cofactor for gamma-carboxylation of clotting factors
VKORC1Phase 4Anticoagulant Therapy–
China National Center for Cardiovascular DiseasesWarfarin
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
VKORC1Phase 4Anticoagulation–
Population Health Research InstituteWarfarin
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
VKORC1Phase 3Bleeding Post-mechanical Valve ReplacementDec 2028
University of SydneyVitamin K1 (Phytonadione)
Vitamin K-dependent carboxylation factor
VKORC1Phase 3CalciphylaxisDec 2029

Conditions

Bleeding Post-mechanical Valve Replacement (1) Bleeding (1) Atrium; Fibrillation (1) Calciphylaxis (1) Atrial Fibrillation and Flutter (1) Anticoagulant Therapy (1) Anticoagulation (1)

Modalities

small molecule (7)

Companies

Population Health Research Institute (1) Columbia University (1) Hospital Sirio-Libanes (1) University of Sydney (1) Nicholas Carlson (1) University of Michigan (1) China National Center for Cardiovascular Diseases (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.